Literature DB >> 8032147

Neuropeptides and alcohol addiction in monkeys.

J M van Ree1, M Kornet, C Goosen.   

Abstract

Neuropeptides have been implicated in experimental drug addiction. Desglycinamide (Arg8) vasopressin (DGAVP) attenuates heroin and cocaine intake during initiation of drug self-administration in rats. beta-Endorphin is self-administered in rats and a role of endogenous opioids in cocaine reward has been proposed. The present studies deal with voluntary alcohol consumption in monkeys under free choice conditions. Monkeys initiated alcohol drinking within a few days and after a stable drinking pattern was acquired increased their ethanol consumption during a short period following interruption of the alcohol supply (relapse). The alcohol drinking behavior seems under the control of reinforcement principles. DGAVP reduced the acquisition of alcohol drinking in the majority of treated monkeys. Initiation of alcohol drinking induced modifications in neuroendocrine homeostasis e.g. an increased plasma beta-endorphin. Both the opioid antagonist naltrexone and the opioid agonist morphine dose-dependently decreased alcohol intake during continuous supply and after imposed abstinence. The monkeys were more sensitive to both drugs after imposed abstinence. The effects are interpreted in the context of the endorphin compensation hypothesis of addictive behavior. It is suggested that endorphins may be particularly implicated in craving for addictive drugs and in relapse of addictive behavior.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8032147     DOI: 10.1007/978-3-0348-7330-7_17

Source DB:  PubMed          Journal:  EXS        ISSN: 1023-294X


  2 in total

1.  Examining naltrexone and alcohol effects in a minority population: results from an initial human laboratory study.

Authors:  Jennifer G Plebani; David W Oslin; Kevin G Lynch
Journal:  Am J Addict       Date:  2011-05-31

Review 2.  Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings.

Authors:  Bankole A Johnson
Journal:  Biochem Pharmacol       Date:  2007-08-09       Impact factor: 5.858

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.